Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JP Morgan analyst Anupam Rama maintains Maze Therapeutics (NASDAQ: MAZE) with a Overweight and raises the price target from ...
HC Wainwright & Co. analyst Ananda Ghosh reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $50 price t...
Guggenheim analyst Debjit Chattopadhyay maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the price target fro...
HC Wainwright & Co. analyst Ananda Ghosh maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the price targe...
BTIG analyst Julian Harrison maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the price target from $30 to $37.
Maze's MZE782 showed strong Phase 1 results, supporting once- or twice-daily dosing with increased amino acid excretion and...
